Long-Acting Propranolol in the Prophylaxis of Migraine: A Comparative Study of Two Doses

Abstract

A randomized double-blind, cross-over study using treatment periods of 12 weeks with a 2-week washout, comparing two long-acting formulations of propranolol (`Inderal’*(1) LA 160 mg daily and Half-‘Inderal’ LA 80 mg daily) was performed after a placebo run-in of 4 weeks on 51 patients. The study indicated that both long-acting formulations were significantly better than placebo in reducing the frequency of migraine attacks ( p < 0.01). After 12 weeks there was a significantly lower ( p = 0.03) frequency of migraine attacks in patients on the higher dose formulation than in those on the lower dose formulation. There was no significant difference in the frequency of side effects produced by the two formulations.